Transdel Pharmaceuticals to Present at 2008 BIOCOM Investor Conference

LA JOLLA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals,
Inc. (OTC Bulletin Board: TDLP) today announced that President and Chief
Executive Officer Dr. Juliet Singh will present a company overview at the
BIOCOM Investor Conference at 10:00 a.m. PDT on Tuesday, October 28, 2008 at
the Hyatt Regency La Jolla in San Diego, CA.

Interested parties can access a live audio webcast via the Internet by
visiting the Investor Relations section of the Company's Web site at
http://www.transdelpharma.com.

About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical
company developing non-invasive, topically- delivered medications. The
Company's innovative patented proprietary Transdel(TM) cream formulation
technology is designed to facilitate the effective penetration of drugs
through the tough skin barrier to reach the target underlying tissues. In the
case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient
ketoprofen to reach the target soft tissue and exert its well-known
anti-inflammatory and analgesic effects. The Company is also investigating
other drug candidates and treatments for transdermal delivery using the
patented Transdel(TM) platform technology for products in pain management and
other therapeutic areas. For more information, please visit
www.transdelpharma.com.

Safe Harbor Statement
The statements which are not historical facts contained in this press release
are forward-looking statements that involve certain risks and uncertainties
including but not limited to risks associated with the uncertainty of future
financial results, additional financing requirements, development of new
products, government approval processes, the impact of competitive products or
pricing, technological changes, the effect of economic conditions and other
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission.

SOURCE Transdel Pharmaceuticals, Inc.

John Lomoro, CFO of Transdel Pharmaceuticals, Inc., +1-858-457-5300,
johnl@transdelpharma.com